SKC podcast

#16 WODC 2023 - News from the annual class reunion of the orphan drug scene

2023 / 11 / 19
The largest World Orphan Drug Congress to date took place in Barcelona at the beginning of November.

Prof. Dr. Matthias P. Schönermark reports on the ever-present topics affordability and gene therapies. He interviewed Matthias Heck, director of global government affairs at Alexion Pharmaceuticals, Sheela Upadhyaya from Fipra and Dr. Nick Sireau, founder of the AKU Society, about the EU pharmaceutical package, the unmet medical need and the influence that patient organizations can make.

You can find Profcast #16 WODC 2023 - News from the annual class reunion of the orphan drug scene on Spotify and Apple Podcast (in German language only). Tune in!

Please click to load Contents from Spotify. Personal data may be transferred to the provider.

About the Profcast

Our SKC podcast series "The Profcast - rare diseases and their therapies" aims to address the special circumstances of patients with rare diseases, the associated medicine and the challenges for research, development, economics and reimbursement. For this purpose, Prof. Matthias P. Schönermark, M.D., Ph.D., managing director of SKC, speaks with patient representatives, payers, clinicians and scientists as well as industry representatives and also focuses on specific diseases. The word Profcast is a reference to professionals or professors, whom he welcomes as his guests.

The ambition behind this is to give an appropriate space to rare diseases and their treatment sine ira et studio. After all, the motto of the Rare Disease Day states it so aptly: "Rare is many". It is estimated that 4 million people in Germany and 300 million people worldwide are affected by a rare disease. In keeping with the Rare Disease Day, which traditionally takes place on the last day of February, the Profcast is published on the last day of a month.

Please click to load Contents from Spotify. Personal data may be transferred to the provider.

About the author

Ihr Ansprechpartner Univ.-Prof. Dr. med. Matthias P. Schönermark
Univ.-Prof. Dr. med. Matthias P. Schönermark
Gründer und Geschäftsführer
Fon: +49 511 64 68 14 – 0
Fax: +49 511 64 68 14 18

Orphan Drugs


Orphan drugs and the specific market access challenges are at the core of our expertise.

Whitepaper


Successful market access for gene therapies - Strategic challenges and possible solutions
to the top